tetano
Editor, Senior Moderator
Nucleic Acids Res
. 2023 Oct 27:gkad912.
doi: 10.1093/nar/gkad912. Online ahead of print. VarEPS-Influ:an risk evaluation system of occurred and virtual variations of influenza virus genomes
Chang Shu[SUP] 1 2 [/SUP], Qinglan Sun[SUP] 1 3 [/SUP], Guomei Fan[SUP] 1 3 [/SUP], Kesheng Peng[SUP] 1 3 [/SUP], Zhengfei Yu[SUP] 1 3 [/SUP], Yingfeng Luo[SUP] 1 2 4 [/SUP], Shenghan Gao[SUP] 1 2 [/SUP], Juncai Ma[SUP] 1 2 3 [/SUP], Tao Deng[SUP] 1 5 [/SUP], Songnian Hu[SUP] 1 2 4 [/SUP], Linhuan Wu[SUP] 1 2 3 [/SUP]
Affiliations
Influenza viruses undergo frequent genomic mutations, leading to potential cross-species transmission, phenotypic changes, and challenges in diagnostic reagents and vaccines. Accurately evaluating and predicting the risk of such variations remain significant challenges. To address this, we developed the VarEPS-Influ database, an influenza virus variations risk evaluation system (VarEPS-Influ). This database employs a 'multi-dimensional evaluation of mutations' strategy, utilizing various tools to assess the physical and chemical properties, primary, secondary, and tertiary structures, receptor affinity, antibody binding capacity, antigen epitopes, and other aspects of the variation's impact. Additionally, we consider space-time distribution, host species distribution, pedigree analysis, and frequency of mutations to provide a comprehensive risk evaluation of mutations and viruses. The VarEPS-Influ database evaluates both observed variations and virtual variations (variations that have not yet occurred), thereby addressing the time-lag issue in risk predictions. Our current one-stop evaluation system for influenza virus genomic variation integrates 1065290 sequences from 224 927 Influenza A, B and C isolates retrieved from public resources. Researchers can freely access the data at https://nmdc.cn/influvar/.
. 2023 Oct 27:gkad912.
doi: 10.1093/nar/gkad912. Online ahead of print. VarEPS-Influ:an risk evaluation system of occurred and virtual variations of influenza virus genomes
Chang Shu[SUP] 1 2 [/SUP], Qinglan Sun[SUP] 1 3 [/SUP], Guomei Fan[SUP] 1 3 [/SUP], Kesheng Peng[SUP] 1 3 [/SUP], Zhengfei Yu[SUP] 1 3 [/SUP], Yingfeng Luo[SUP] 1 2 4 [/SUP], Shenghan Gao[SUP] 1 2 [/SUP], Juncai Ma[SUP] 1 2 3 [/SUP], Tao Deng[SUP] 1 5 [/SUP], Songnian Hu[SUP] 1 2 4 [/SUP], Linhuan Wu[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 37889020
- DOI: 10.1093/nar/gkad912
Influenza viruses undergo frequent genomic mutations, leading to potential cross-species transmission, phenotypic changes, and challenges in diagnostic reagents and vaccines. Accurately evaluating and predicting the risk of such variations remain significant challenges. To address this, we developed the VarEPS-Influ database, an influenza virus variations risk evaluation system (VarEPS-Influ). This database employs a 'multi-dimensional evaluation of mutations' strategy, utilizing various tools to assess the physical and chemical properties, primary, secondary, and tertiary structures, receptor affinity, antibody binding capacity, antigen epitopes, and other aspects of the variation's impact. Additionally, we consider space-time distribution, host species distribution, pedigree analysis, and frequency of mutations to provide a comprehensive risk evaluation of mutations and viruses. The VarEPS-Influ database evaluates both observed variations and virtual variations (variations that have not yet occurred), thereby addressing the time-lag issue in risk predictions. Our current one-stop evaluation system for influenza virus genomic variation integrates 1065290 sequences from 224 927 Influenza A, B and C isolates retrieved from public resources. Researchers can freely access the data at https://nmdc.cn/influvar/.